The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Vera Therapeutics Inc (NASDAQ: VERA) closed the day trading at $22.01 down -13.79% from the previous closing price of $25.53. In other words, the price has decreased by -$13.79 from its previous closing price. On the day, 4.14 million shares were traded.
Ratios:
For a better understanding of VERA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 25.58 and its Current Ratio is at 25.58. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $49.
On January 28, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $58.Goldman initiated its Buy rating on January 28, 2025, with a $58 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 21 ’25 when Fordyce Marshall sold 10,613 shares for $27.89 per share. The transaction valued at 296,032 led to the insider holds 213,740 shares of the business.
Fordyce Marshall sold 9,075 shares of VERA for $250,882 on Feb 26 ’25. The PRESIDENT AND CEO now owns 204,665 shares after completing the transaction at $27.65 per share. On Feb 26 ’25, another insider, MARSHALL FORDYCE, who serves as the Director of the company, bought 9,075 shares for $27.10 each.
Stock Price History:
Over the past 52 weeks, VERA has reached a high of $51.61, while it has fallen to a 52-week low of $18.53. The 50-Day Moving Average of the stock is -12.21%, while the 200-Day Moving Average is calculated to be -39.55%.
Shares Statistics:
A total of 63.56M shares are outstanding, with a floating share count of 48.96M. Insiders hold about 23.22% of the company’s shares, while institutions hold 90.99% stake in the company.
